Literature DB >> 3768259

Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man.

P Chiodera, R Volpi, R Delsignore, C Marchesi, G Salati, L Camellini, G Rossi, V Coiro.   

Abstract

This study was performed in order to investigate the dopaminergic mechanism involved in the control of arginine-vasopressin (AVP) secretion in normal men. Plasma AVP concentrations were measured before and after the administration of an i.v. bolus of 10 mg metoclopramide or domperidone to twelve healthy males. Metoclopramide, a cerebral and peripheral antagonist of dopaminergic receptors, significantly stimulated AVP secretion, whereas domperidone, a dopamine antagonist which does not cross the blood-brain barrier, was without effect. These data suggest that metoclopramide stimulates the release of AVP by blocking dopaminergic receptors in structures located inside the blood-brain barrier. Alternatively, it is possible that the stimulation of AVP release induced by metoclopramide does not occur through inhibition of dopamine receptors but rather through interaction with other neuroendocrine pathways.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768259      PMCID: PMC1401167          DOI: 10.1111/j.1365-2125.1986.tb02921.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Metoclopramide and dopamine receptor blockade.

Authors:  R Miller
Journal:  Neuropharmacology       Date:  1976-08       Impact factor: 5.250

2.  A new hypothalamic pathway to the median eminence containing neurophysin and its hypertrophy in sheep with natural scrapie.

Authors:  H B Parry; B G Livett
Journal:  Nature       Date:  1973-03-02       Impact factor: 49.962

3.  Localization of tritiated dopamine in the median eminence of the rat hypothalamus by electron microscope autoradiography.

Authors:  A C Cuello; L L Iversen
Journal:  Brain Res       Date:  1973-12-07       Impact factor: 3.252

Review 4.  Central nervous system mediators of vasopressin release.

Authors:  A H Sklar; R W Schrier
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

5.  Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.

Authors:  P M Laduron; J E Leysen
Journal:  Biochem Pharmacol       Date:  1979-07-15       Impact factor: 5.858

6.  Effect of metoclopramide in plasma vasopressin in man.

Authors:  K Nomura; F Kurimoto; H Demura; H Sakurai; T Nomura; K Zibiki; M Naruse; N Kanai; K Shizume
Journal:  Clin Endocrinol (Oxf)       Date:  1984-08       Impact factor: 3.478

7.  Uptake of monoamines into central neurones and the blood-brain barrier in the infant rat.

Authors:  L A Loizou
Journal:  Br J Pharmacol       Date:  1970-12       Impact factor: 8.739

8.  Vasopressin and neurophysin: high concentrations in monkey hypophyseal portal blood.

Authors:  E A Zimmerman; P W Carmel; M K Husain; M Ferin; M Tannenbaum; A G Frantz; A G Robinson
Journal:  Science       Date:  1973-11-20       Impact factor: 47.728

9.  The effect of pizotifen, a serotonin antagonist, and of pirenzepine, a muscarinic antagonist, on hormonal responses to metoclopramide in healthy subjects.

Authors:  E Jungmann; P H Althoff; G J Hermann; K Schöffling
Journal:  Arzneimittelforschung       Date:  1984

10.  A serotonergic mechanism of the prolactin-stimulating action of metoclopramide.

Authors:  V S Fang; L R Shian
Journal:  Endocrinology       Date:  1981-05       Impact factor: 4.736

View more
  1 in total

Review 1.  Domperidone. A review of its use in diabetic gastropathy.

Authors:  A Prakash; A J Wagstaff
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.